Latest news with #ThomasO'Shaughnessy
Business Wire
22-05-2025
- Business
- Business Wire
Onco-Innovations Uplists to Cboe Canada
TORONTO--(BUSINESS WIRE)-- Cboe Canada Inc. ('Cboe Canada') is pleased to announce that Onco-Innovations Limited ('Onco'), a Canadian-based company dedicated to cancer research and treatment, has uplisted to Cboe Canada and is available for trading under the ticker symbol ONCO. Onco has a core mission to prevent and cure cancer through cutting edge science. The company holds an exclusive global license to patented technology targeting solid tumors — and is now expanding into AI-driven analytics for multimodal real-world data. 'Onco-Innovations is at a pivotal stage,' said Thomas O'Shaughnessy, CEO of Onco. 'Our growth now extends beyond drug development into AI-powered research, with a view to creating faster, smarter pathways to new cancer therapies. This convergence of science and technology positions Onco as a next-generation oncology company ready to tackle some of the biggest challenges in the field.' 'Joining Cboe is more than a listing — it's a strategic alignment,' added O'Shaughnessy. 'It gives us the tools to deepen investor engagement, expand our network, and accelerate our journey toward transforming the future of cancer therapy.' Cboe Canada's commitment to supporting innovative, high-growth companies and delivering global reach makes it a natural partner for Onco's ambitious vision. 'It is an honour to welcome Onco to the growing roster of Cboe Listed issuers,' remarked Tanya Rowntree, Head of Listings at Cboe Canada. 'Their move to a Tier 1 listing on Cboe reflects both their strategic growth trajectory and the confidence in our platform to support next-generation innovators. Onco now benefits from enhanced access to capital, greater liquidity, and increased visibility among investors and institutions alike.' Investors can trade shares of ONCO through their usual investment channels, including discount brokerages and full-service dealers. To explore all listed securities on Cboe Canada, click here. Cboe Canada is home to some of the most innovative Canadian and international growth companies, ETFs from Canada's largest ETF issuers, and more than 120 Canadian Depositary Receipts (CDRs). Cboe consistently facilitates 15% of all volume traded in Canadian listed securities. About Cboe Canada Cboe Canada is Canada's Tier 1 stock exchange providing a best-in-class listing experience for issuers that are shaping the economies of tomorrow. Fully operational since 2015, Cboe Canada lists companies and investment products seeking a robust and internationally recognized platform that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data. Cboe Canada is part of Cboe Global Markets, the leading securities and derivatives exchange for the world stage. With exchanges in North America, Europe and Asia Pacific, Cboe is harnessing its global network to equip Issuers with essential capital markets solutions. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco is focused on advancing personalized therapies that improve cancer outcomes and set new standards in oncology research.
Yahoo
16-05-2025
- Business
- Yahoo
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
VANCOUVER, BC / / May 16, 2025 / Onco-Innovations Limited (CSE:ONCO) ("Onco" or the "Company") is pleased to announce that it will transfer the listing of its common shares (the "Common Shares") to Cboe Canada Inc. ("Cboe Canada") from the Canadian Securities Exchange ("CSE"). Onco expects its Common Shares to begin trading on Cboe Canada on May 22, 2025 under its existing ticker symbol "ONCO", and the Company has submitted a request to voluntarily delist its Common Shares from the CSE, which is expected to take effect at the close of trading on May 21, 2025. No action is required from shareholders regarding this transition. Cboe Canada, a Tier 1 stock exchange and part of the global Cboe Markets network, offers a robust and internationally recognized platform for innovative companies seeking investor trust, liquidity, and visibility. Since launching in 2015, Cboe Canada has supported issuers through advanced market infrastructure and access to real-time data solutions, including its ETF Market Canada platform - an institutional-grade resource for exploring and analyzing over 1,200 Canadian ETFs. Real-time quotes and market information on Onco-Innovations can be found at "Our move to Cboe Canada is a pivotal step in Onco-Innovations' journey as we scale our operations and deepen our commitment to developing impactful oncology solutions. This listing will not only enhance our visibility within the capital markets but also place us alongside a growing roster of forward-thinking companies focused on long-term value creation. We see this as an opportunity to broaden our investor base, strengthen engagement with institutions, and ensure that our capital strategy evolves in step with our scientific ambitions," stated Thomas O'Shaughnessy, CEO of the Company. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, Thomas O'ShaughnessyChief Executive Officer For more information, please contact: Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@ The CSE and Cboe Canada have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the commencement of trading of the Common Shares on Cboe Canada, the Company's request to voluntarily delist the Common Shares from the CSE, and the Company's future goals and objectives. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain acts, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks relating to transferring the Company's listing of its Common Shares from the CSE to Cboe Canada, the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all. Accordingly, readers should not place undue reliance on any such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. SOURCE: Onco-Innovations Limited View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
25-03-2025
- Business
- Associated Press
Onco-Innovations Extends Marketing Program
VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ('Onco' or the 'Company') announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: [email protected]; telephone: +491772481220; and website: ('MCS') for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the 'Services'). The Services are expected to run until May 31, 2025, or until budget exhaustion. The Company has paid MCS CAD 600,000 for the extended term of Services, and no securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the Company's ability to complete future research and development activities with respect thereto, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, the failure to complete further research and development activities in respect thereto, the failure to receive regulatory approval in respect of its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Yahoo
04-03-2025
- Yahoo
Salem man found with weapon in car, charged with OUI
SALEM, Conn. (WTNH) — A Salem man was arrested and charged with OUI and a weapon was found during a traffic stop early Tuesday morning in Colchester, according to police. Thomas O'Shaughnessy, 24, was allegedly speeding and swerving between lanes on Route 2 eastbound, according to police. State Rep. Aundré Bumgardner arrested for DUI During the traffic stop, police searched the vehicle and found a 12-inch katana-style blade on the floorboard of the car. O'Shaughnessy was charged with OUI, speeding, weapon in a motor vehicle and other violations. He was released on $5,000 bond and will appear at Norwich Superior Court on March 25. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press
02-03-2025
- Business
- Associated Press
Onco-Innovations CEO Thomas O'Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program showcasing thought leaders shaping the world. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British Columbia, Canada, including CHEK-TV, as well as on digital platforms. In this exclusive interview, O'Shaughnessy shared Onco-Innovations' efforts towards developing a novel treatment candidate for colorectal cancer and other solid tumours, as well as the Company's distinguished scientific team, its recent strategic acquisition of Inka Health AI, and the Company's progress toward advancing clinical trials. The interview delved into Onco-Innovations' pioneering approach to research and development regarding cancer treatment, which focuses on precision medicine to enhance the effectiveness of traditional therapies such as chemotherapy and radiation. O'Shaughnessy highlighted the Company's proprietary technology, developed by leading scientists from the University of Alberta Cancer Institute, including the use of targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue. He also discussed how the recently-acquired Inka Health AI is developing tools to leverage artificial intelligence to optimize patient identification and enhance clinical trial efficacy. Through this acquisition, he added, Onco-Innovations will continue to focus on building partnerships with research organizations such as Quantify Research, and big-pharma, such as AstraZeneca Canada, collaborations that the Company believes will play a crucial role in advancing a precision medicine approach to cancer therapeutic development. 'Being featured on Conversations That Matter gives us an incredible opportunity to share Onco-Innovations' story and reach a broader audience. It's vital for us to communicate the novel work we're doing in precision cancer therapeutic development and how we're striving to develop innovative therapies,' said Thomas O'Shaughnessy, CEO of Onco-Innovations. 'We are committed to advancing our research, accelerating clinical trials, and ultimately making a global impact in the fight against cancer.' You can watch the interview online at the Conversations That Matter website, their YouTube channel, their Vimeo channel, and the Vancouver Sun website. It will also be broadcast on British Columbia based stations, CHEK-TV, CFTK-TV, CJDC-TV, and CKFR-AM. Please check the individual station websites for specific air dates and times. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer. ON BEHALF OF ONCO-INNOVATIONS LIMITED, 'Thomas O'Shaughnessy' Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release. Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's research initiatives, and the prospects of the Company, including its ability to safeguard its technologies, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize any of the Company's technologies, the failure to receive a patent or to otherwise safeguard the Company's intellectual property rights, the failure to successfully complete further trials and studies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
